MetaCap

Apnimed (APMD) vs Sagimet Biosciences Series A (SGMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apnimed is the larger company by market cap ($669.8 million vs $648.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-35.64%SGMT+27.71%
+66%+9%-49%
Jul 31, 20261 yearNov 20, 2026
APMD-35.64%SGMT+27.71%
+61%+8%-44%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus SGMT key metrics
MetricAPMDSGMT
Share price$16.09$9.08
Market cap$669.84M$648.02M
1-day change-6.70%-5.61%
YTD return—+53.38%
1-year return—+36.13%
P/E ratio (TTM)1.21—
EPS (TTM)$13.34$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-51.04M
52-week high$35.29$11.45
52-week low$13.88$4.50
Distance from 52-week high-54.41%-20.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+210.75%+200.33%
Average volume458.58K1.23M
Shares outstanding41.63M71.37M
Employees11216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

About Sagimet Biosciences Series A

SGMT stock →

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

APMD vs SGMT FAQ

Which is bigger, Apnimed or Sagimet Biosciences Series A?

Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $648.02M for Sagimet Biosciences Series A (SGMT).

Are Apnimed and Sagimet Biosciences Series A in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons